trending Market Intelligence /marketintelligence/en/news-insights/trending/om7hs_yg-x6logx_wzkgow2 content esgSubNav
In This List

Bone Biologics enters stock, debt purchase agreement with Hankey Capital

Blog

Global M&A By the Numbers: Q3 2021

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond

Blog

University Essentials: From Crisis to Resilience – Navigating Sustainable Recovery

Blog

EV impact; vaccines to boost job market; coal supply constraints


Bone Biologics enters stock, debt purchase agreement with Hankey Capital

Bone Biologics Corp. agreed to sell up to 3,869,979 common shares at $1 each to Hankey Capital LLC.

The Burlington, Mass.-based medical device company also agreed to issue a convertible secured note due Dec. 31, 2019, worth up to $2 million.

The note is convertible into Bone Biologics common stock at $1 per share and will have an interest at a prime rate or 8.5% annually, whichever is greater.

The purchase agreement with Hankey Capital will close on the later of July 16, or when the company implements its 1-for-10 reverse stock split.